SCM
ORIC icon

Suvretta Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Suvretta Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-255,000
Closed -$1.42M – 103
2025
Q1 		$1.42M Buy
+255,000
New +$2.23M 0.05% 82
2023
Q3 		– Sell
-492,924
Closed -$3.83M – 100
2023
Q2 		$3.83M Sell
492,924
-1,409,719
-74% -$8.01M 0.2% 64
2023
Q1 		$10.8M Hold
1,902,643
– – 0.46% 50
2022
Q4 		$11.2M Hold
1,902,643
– – 0.47% 50
2022
Q3 		$6.09M Buy
1,902,643
+640,179
+51% +$2.56M 0.25% 54
2022
Q2 		$5.66M Buy
1,262,464
+821,768
+186% +$3.28M 0.22% 62
2022
Q1 		$2.35M Hold
440,696
– – 0.07% 72
2021
Q4 		$6.48M Buy
440,696
+291,596
+196% +$4.55M 0.13% 70
2021
Q3 		$3.12M Buy
+149,100
New +$3.02M 0.05% 85
2021
Q1 		– Sell
-252,910
Closed -$8.56M – 125
2020
Q4 		$8.56M Buy
+252,910
New +$7.26M 0.12% 64
2020
Q3 		– Sell
-76,432
Closed -$2.58M – 112
2020
Q2 		$2.58M Buy
+76,432
New +$2.44M 0.06% 67

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Suvretta Capital Management's ORIC Position: Q2 2025 in Review

Suvretta Capital Management sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 255,000 shares — an estimated $1.42M sold.

Suvretta Capital Management first reported a position in ORIC in Q2 2020 and held it in 11 quarters. The position peaked at $11.2M in Q4 2022. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

  • Suvretta Capital Management reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Suvretta Capital Management sold 255,000 Oric Pharmaceuticals shares in Q2 2025, an estimated $1.42M.
  • Suvretta Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 11 quarters.
  • Suvretta Capital Management's Oric Pharmaceuticals position peaked at $11.2M in Q4 2022.
  • 142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.